Summary
4.87
0.17
(3.62%)
04/13/2026
SOPHiA GENETICS S.A. (SOPH)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years |
| 3.62 | -5.05 | 4.68 | -8.74 | 12.44 | 68.46 | -71.96 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan!
Fundamental Ratings
| Category | Rating |
| Main Rating | D+ |
| Recommended Rating | Strong Sell |
| DCF | Strong Sell |
| ROE | Strong Sell |
| ROA | Strong Sell |
| Debt/Equity | Strong Sell |
| P/E | Strong Sell |
| P/B | Strong Sell |
Earnings
| Trading Data | ||
| Close | 4.87 | |
| Open | 4.66 | |
| High | 4.89 | |
| Low | 4.66 | |
| Volume | 82,730 | |
| Change | 0.17 | |
| Change % | 3.62 | |
| Avg Volume (20 Days) | 93,014 | |
| Volume/Avg Volume (20 Days) Ratio | 0.89 | |
| 52 Week Range | 2.58 - 5.70 | |
| Price vs 52 Week High | -14.56% | |
| Price vs 52 Week Low | 88.76% | |
| Range | -1.05 | |
| Gap Up/Down | -0.15 | |
Profitibility | ||
| Market Capitalization (Mln) | 297 | |
| Revenue per share | 1.1323 | |
| Net Income per share | -1.1576 | |
| Dividend Yield | 0.0000 | |
| Dividend Share | 0.00% | |
Valuations | ||
| Enterprise Value | 0.00% | |
| PE Ratio | -4.0600 | |
| PB Ratio | 0.0000 | |
| PTB Ratio | 0.0000 | |
Liquidity | ||
| Debt/Equity Ratio | 0.0000 | |
| Net Debt/EBIDTA Ratio | 0.0000 | |
| Current Ratio | 0.0000 | |
Enterprise Value and Cash Flow | ||
| EV/Sales Ratio | 0.0000 | |
| EV/EBIDTA Ratio | 0.0000 | |
| EV/Free Cash Flow Ratio | 0.0000 | |
03/15 01:58 EST - defenseworld.net
SOPHiA GENETICS (NASDAQ:SOPH) & Hims & Hers Health (NYSE:HIMS) Financial Comparison
Hims and Hers Health (NYSE: HIMS - Get Free Report) and SOPHiA GENETICS (NASDAQ: SOPH - Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, dividends, valuation, risk, institutional ownership,...
SOPHiA GENETICS (NASDAQ:SOPH) & Hims & Hers Health (NYSE:HIMS) Financial Comparison
Hims and Hers Health (NYSE: HIMS - Get Free Report) and SOPHiA GENETICS (NASDAQ: SOPH - Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, dividends, valuation, risk, institutional ownership,...
03/05 02:34 EST - defenseworld.net
SOPHiA GENETICS Q4 Earnings Call Highlights
SOPHiA GENETICS (NASDAQ: SOPH) executives highlighted accelerating commercial momentum, expanding platform capabilities, and improved profitability outlook during the company's fourth-quarter and full-year 2025 earnings call. Management also discussed leadership changes, major customer wins, and...
SOPHiA GENETICS Q4 Earnings Call Highlights
SOPHiA GENETICS (NASDAQ: SOPH) executives highlighted accelerating commercial momentum, expanding platform capabilities, and improved profitability outlook during the company's fourth-quarter and full-year 2025 earnings call. Management also discussed leadership changes, major customer wins, and...
03/03 12:32 EST - seekingalpha.com
SOPHiA GENETICS SA (SOPH) Q4 2025 Earnings Call Transcript
SOPHiA GENETICS SA (SOPH) Q4 2025 Earnings Call Transcript
SOPHiA GENETICS SA (SOPH) Q4 2025 Earnings Call Transcript
SOPHiA GENETICS SA (SOPH) Q4 2025 Earnings Call Transcript
03/03 06:45 EST - prnewswire.com
SOPHiA GENETICS Reports Fourth Quarter and Full Year 2025 Results
BOSTON and ROLLE, Switzerland, March 3, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the fourth quarter and fiscal year ended December 31, 2025. Fourth Quarter 2025 Financial Results Revenue was $21.7...
SOPHiA GENETICS Reports Fourth Quarter and Full Year 2025 Results
BOSTON and ROLLE, Switzerland, March 3, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the fourth quarter and fiscal year ended December 31, 2025. Fourth Quarter 2025 Financial Results Revenue was $21.7...
02/25 08:00 EST - prnewswire.com
SOPHiA GENETICS to Present at the 46th Annual TD Cowen Health Care Conference
BOSTON and ROLLE, Switzerland, Feb. 25, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today announced that leadership will present at TD Cowen's 46th Annual Health Care Conference in Boston. Jurgi Camblong, Chief Executive Officer and...
SOPHiA GENETICS to Present at the 46th Annual TD Cowen Health Care Conference
BOSTON and ROLLE, Switzerland, Feb. 25, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today announced that leadership will present at TD Cowen's 46th Annual Health Care Conference in Boston. Jurgi Camblong, Chief Executive Officer and...
02/17 08:00 EST - prnewswire.com
SOPHiA GENETICS to Announce Financial Results for Fourth Quarter and Full Year 2025 on March 3, 2026
BOSTON and ROLLE, Switzerland, Feb. 17, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today announced it will release its financial results for the fourth quarter and full year 2025 before U.S. markets open on Tuesday, March 3, 2026. On that...
SOPHiA GENETICS to Announce Financial Results for Fourth Quarter and Full Year 2025 on March 3, 2026
BOSTON and ROLLE, Switzerland, Feb. 17, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today announced it will release its financial results for the fourth quarter and full year 2025 before U.S. markets open on Tuesday, March 3, 2026. On that...
02/10 09:22 EST - prnewswire.com
SOPHiA GENETICS Announces Major Expansion in the United States with the Signing of Two Major Integrated Health Systems
BOSTON and ROLLE, Switzerland, Feb. 10, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, today announced the addition of two of the largest U.S. healthcare systems to its network. The two new institutions, which collectively analyze millions of...
SOPHiA GENETICS Announces Major Expansion in the United States with the Signing of Two Major Integrated Health Systems
BOSTON and ROLLE, Switzerland, Feb. 10, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, today announced the addition of two of the largest U.S. healthcare systems to its network. The two new institutions, which collectively analyze millions of...
02/02 01:43 EST - defenseworld.net
Comparing SOPHiA GENETICS (NASDAQ:SOPH) & Precipio (NASDAQ:PRPO)
Precipio (NASDAQ: PRPO - Get Free Report) and SOPHiA GENETICS (NASDAQ: SOPH - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, valuation, earnings, analyst...
Comparing SOPHiA GENETICS (NASDAQ:SOPH) & Precipio (NASDAQ:PRPO)
Precipio (NASDAQ: PRPO - Get Free Report) and SOPHiA GENETICS (NASDAQ: SOPH - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, valuation, earnings, analyst...
02/01 01:10 EST - defenseworld.net
SOPHiA GENETICS (NASDAQ:SOPH) versus Pulmonx (NASDAQ:LUNG) Critical Comparison
SOPHiA GENETICS (NASDAQ: SOPH - Get Free Report) and Pulmonx (NASDAQ: LUNG - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, dividends, profitability, risk, earnings, analyst...
SOPHiA GENETICS (NASDAQ:SOPH) versus Pulmonx (NASDAQ:LUNG) Critical Comparison
SOPHiA GENETICS (NASDAQ: SOPH - Get Free Report) and Pulmonx (NASDAQ: LUNG - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, dividends, profitability, risk, earnings, analyst...
01/27 03:38 EST - defenseworld.net
1,409,160 Shares in SOPHiA GENETICS SA $SOPH Bought by Alta Wealth Advisors LLC
Alta Wealth Advisors LLC purchased a new stake in SOPHiA GENETICS SA (NASDAQ: SOPH) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 1,409,160 shares of the company's stock, valued at approximately...
1,409,160 Shares in SOPHiA GENETICS SA $SOPH Bought by Alta Wealth Advisors LLC
Alta Wealth Advisors LLC purchased a new stake in SOPHiA GENETICS SA (NASDAQ: SOPH) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 1,409,160 shares of the company's stock, valued at approximately...
01/12 07:00 EST - prnewswire.com
SOPHiA GENETICS Provides Preliminary Fourth Quarter and Full Year 2025 Financial Results, Initiates 2026 Guidance, and Announces Executive Transition Plan
The Company finishes 2025 with strong Q4 performance, expects 20-22% revenue growth in 2026, and promotes Ross Muken to CEO BOSTON and ROLLE, Switzerland, Jan. 12, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today provided preliminary...
SOPHiA GENETICS Provides Preliminary Fourth Quarter and Full Year 2025 Financial Results, Initiates 2026 Guidance, and Announces Executive Transition Plan
The Company finishes 2025 with strong Q4 performance, expects 20-22% revenue growth in 2026, and promotes Ross Muken to CEO BOSTON and ROLLE, Switzerland, Jan. 12, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today provided preliminary...
01/12 01:28 EST - defenseworld.net
Analyzing MSP Recovery (NASDAQ:MSPR) & SOPHiA GENETICS (NASDAQ:SOPH)
SOPHiA GENETICS (NASDAQ: SOPH - Get Free Report) and MSP Recovery (NASDAQ: MSPR - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, risk,...
Analyzing MSP Recovery (NASDAQ:MSPR) & SOPHiA GENETICS (NASDAQ:SOPH)
SOPHiA GENETICS (NASDAQ: SOPH - Get Free Report) and MSP Recovery (NASDAQ: MSPR - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, risk,...
01/07 08:00 EST - prnewswire.com
SOPHiA GENETICS and MD Anderson Announce Strategic Collaboration to Accelerate AI-Driven Precision Oncology
BOSTON and HOUSTON, Jan. 7, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration that unites SOPHiA GENETICS' AI-powered analytics with MD Anderson's...
SOPHiA GENETICS and MD Anderson Announce Strategic Collaboration to Accelerate AI-Driven Precision Oncology
BOSTON and HOUSTON, Jan. 7, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration that unites SOPHiA GENETICS' AI-powered analytics with MD Anderson's...
12/27 02:07 EST - defenseworld.net
SOPHiA GENETICS (NASDAQ:SOPH) Trading 2.8% Higher – What’s Next?
Shares of SOPHiA GENETICS SA (NASDAQ: SOPH - Get Free Report) shot up 2.8% during mid-day trading on Friday. The company traded as high as $4.75 and last traded at $4.73. 45,371 shares traded hands during trading, a decline of 38% from the average session volume of 73,308 shares. The stock had...
SOPHiA GENETICS (NASDAQ:SOPH) Trading 2.8% Higher – What’s Next?
Shares of SOPHiA GENETICS SA (NASDAQ: SOPH - Get Free Report) shot up 2.8% during mid-day trading on Friday. The company traded as high as $4.75 and last traded at $4.73. 45,371 shares traded hands during trading, a decline of 38% from the average session volume of 73,308 shares. The stock had...
12/07 03:02 EST - defenseworld.net
Comparing SOPHiA GENETICS (NASDAQ:SOPH) and Azenta (NASDAQ:AZTA)
Azenta (NASDAQ: AZTA - Get Free Report) and SOPHiA GENETICS (NASDAQ: SOPH - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, analyst recommendations,...
Comparing SOPHiA GENETICS (NASDAQ:SOPH) and Azenta (NASDAQ:AZTA)
Azenta (NASDAQ: AZTA - Get Free Report) and SOPHiA GENETICS (NASDAQ: SOPH - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, analyst recommendations,...
11/11 09:00 EST - prnewswire.com
SOPHiA GENETICS and Complete Genomics Integrate Sequencing and AI Analytics to Accelerate Adoption of Precision Medicine
BOSTON , Nov. 11, 2025 /PRNewswire/ -- Complete Genomics, a leading innovator in genomic sequencing, today announced a collaboration with SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, to launch and co-market MSK-ACCESS® and MSK-IMPACT® powered with SOPHiA DDM™...
SOPHiA GENETICS and Complete Genomics Integrate Sequencing and AI Analytics to Accelerate Adoption of Precision Medicine
BOSTON , Nov. 11, 2025 /PRNewswire/ -- Complete Genomics, a leading innovator in genomic sequencing, today announced a collaboration with SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, to launch and co-market MSK-ACCESS® and MSK-IMPACT® powered with SOPHiA DDM™...
11/11 08:01 EST - prnewswire.com
SOPHiA GENETICS and Element Biosciences Unite Sequencing Power and AI Analytics to Accelerate Global Research In Precision Medicine
BOSTON and SAN DIEGO , Nov. 11, 2025 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, and Element Biosciences, Inc., a biology company transforming the pace and accessibility of scientific discovery, today announced at the Association for Molecular...
SOPHiA GENETICS and Element Biosciences Unite Sequencing Power and AI Analytics to Accelerate Global Research In Precision Medicine
BOSTON and SAN DIEGO , Nov. 11, 2025 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, and Element Biosciences, Inc., a biology company transforming the pace and accessibility of scientific discovery, today announced at the Association for Molecular...
11/04 13:56 EST - seekingalpha.com
SOPHiA GENETICS SA (SOPH) Q3 2025 Earnings Call Transcript
SOPHiA GENETICS SA ( SOPH ) Q3 2025 Earnings Call November 4, 2025 8:00 AM EST Company Participants Kellen Sanger - Head of Strategy and Investor Relations Jurgi Camblong - Co-Founder, CEO & Director Ross Muken - President George Cardoza - Executive VP & CFO Conference Call Participants William...
SOPHiA GENETICS SA (SOPH) Q3 2025 Earnings Call Transcript
SOPHiA GENETICS SA ( SOPH ) Q3 2025 Earnings Call November 4, 2025 8:00 AM EST Company Participants Kellen Sanger - Head of Strategy and Investor Relations Jurgi Camblong - Co-Founder, CEO & Director Ross Muken - President George Cardoza - Executive VP & CFO Conference Call Participants William...
11/04 06:45 EST - prnewswire.com
SOPHiA GENETICS Reports Third Quarter 2025 Results and Increases 2025 Revenue Guidance
BOSTON and ROLLE, Switzerland , Nov. 4, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Results Revenue was $19.5 million, up 23%...
SOPHiA GENETICS Reports Third Quarter 2025 Results and Increases 2025 Revenue Guidance
BOSTON and ROLLE, Switzerland , Nov. 4, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Results Revenue was $19.5 million, up 23%...
10/21 08:00 EST - prnewswire.com
SOPHiA GENETICS to Announce Financial Results for Third Quarter 2025 on November 4, 2025
BOSTON and ROLLE, Switzerland , Oct. 21, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today announced it will release its financial results for the third quarter 2025 before U.S. markets open on Tuesday, November 4, 2025. On that day, SOPHiA...
SOPHiA GENETICS to Announce Financial Results for Third Quarter 2025 on November 4, 2025
BOSTON and ROLLE, Switzerland , Oct. 21, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today announced it will release its financial results for the third quarter 2025 before U.S. markets open on Tuesday, November 4, 2025. On that day, SOPHiA...
Market News
×
Loading news…